Last updated 9 days ago

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

275 patients around the world
Available in Chile, United States, Spain
Merck Sharp & Dohme LLC
5Research sites
275Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Non-Hodgkin Lymphoma
Mantle cell lymphoma
Follicular lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Estudios Clínicos SAGA - CECSAGA
Recruiting
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
Instituto Catalan de Oncologia - ICO - Badalona
Recruiting
Carretera de Can Ruti, 21A, 08916 Badalona, Barcelona
Hospital Duran i Reynals
Recruiting
Avinguda de la Granvia de l’Hospitalet, 199, 08908 L'Hospitalet de Llobregat
Hospital Vall de Hebrón
Recruiting
Pg. de la Vall d'Hebron, 119, 129, 08035 Barcelona, Spain
Hospital Clínico Universitario de Salamanca
Recruiting
Paseo de San Vicente, 182, 37007 Salamanca, España
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy